The effects of methylphenidate on knockin mice with a methylphenidate- resistant dopamine transporter

Journal of Pharmacology and Experimental Therapeutics

Volumn 327, Issue 2, 2008, Pages 554-560

  Tilley, Michael R ^a,b   Gu, Howard H ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b Central Methodist University   (United States)

^c 5184B Graves Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DESIPRAMINE; DOPAMINE TRANSPORTER; METHYLPHENIDATE; MUTANT PROTEIN; NISOXETINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONDITIONING; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; REWARD; STEREOTYPY;

ANIMALS; COCAINE; CONDITIONING (PSYCHOLOGY); DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG RESISTANCE; MALE; METHYLPHENIDATE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; STEREOTYPED BEHAVIOR;

EID: 54349123839     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.141713     Document Type: Article

References (40)

1. Auclair A, Cotecchia S, Glowinski J, and Tassin JP (2002) D-Amphetamine fails to increase extracellular dopamine levels in mice lacking alpha 1b-adrenergic receptors: relationship between functional and nonfunctional dopamine release. J Neurosci 22:9150-9154.
2. Auclair A, Drouin C, Cotecchia S, Glowinski J, and Tassin JP (2004) 5-HT2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. Eur J Neurosci 20:3073-3084.
3. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, Hamilton C, and Spencer RC (2006) Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 60:1111-1120.
4. Biederman J and Spencer T (1999) Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46:1234-1242.
5. Bruno KJ and Hess EJ (2006) The alpha(2C)-adrenergic receptor mediates hyperactivity of coloboma mice, a model of attention deficit hyperactivity disorder. Neurobiol Dis 23:679-688.
6. Carrera MR, Kaufmann GF, Mee JM, Meijler MM, Koob GF, and Janda KD (2004) Treating cocaine addiction with viruses. Proc Natl Acad Sci U S A 101:10416-10421.
7. Chen R, Han DD, and Gu HH (2005) A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate. J Neurochem 94:352-359.
8. Chen R, Tilley MR, Wei H, Zhou F, Zhou FM, Ching S, Quan N, Stephens RL, Hill ER, Nottoli T, et al. (2006) Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc Natl Acad Sci U S A 103:9333-9338.
9. Davis WM, Smith SG, and Khalsa JH (1975) Noradrenergic role in the self-administration of morphine or amphetamine. Pharmacol Biochem Behav 3:477-484.
10. Di Chiara G and Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85:5274-5278.
11. Drouin C, Blanc G, Villégier AS, Glowinski J, and Tassin JP (2002a) Critical role of alpha1-adrenergic receptors in acute and sensitized locomotor effects of D-amphetamine, cocaine, and GBR 12783: influence of preexposure conditions and pharmacological characteristics. Synapse 43:51-61.
12. Drouin C, Darracq L, Trovero F, Blanc G, Glowinski J, Cotecchia S, and Tassin JP (2002b) Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci 22:2873-2884.
13. Giros B, Jaber M, Jones SR, Wightman RM, and Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612.
14. Goodman LS, Gilman A, Brunton LL, Lazo JS, and Parker KL (2006) Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York. Han DD and Gu HH (2006) Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6:6.
15. Jiménez-Rivera CA, Feliu-Mojer M, and Vázquez-Torres R (2006) Alpha-noradrenergic receptors modulate the development and expression of cocaine sensitization. Ann N Y Acad Sci 1074:390-402.
16. Jones BE, Halaris AE, McIlhany M, and Moore RY (1977) Ascending projections of the locus coeruleus in the rat: I. Axonal transport in central noradrenaline neurons. Brain Res 127:1-21.
17. Kollins SH, MacDonald EK, and Rush CR (2001) Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 68:611-627.
18. Kroutil LA, Van Brunt DL, Herman-Stahl MA, Heller DC, Bray RM, and Penne MA (2006) Nonmedical use of prescription stimulants in the united states. Drug Alcohol Depend 84:135-143.
19. Kuczenski R and Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68:2032-2037.
20. Lee B, Tiefenbacher S, Platt DM, and Spealman RD (2004) Pharmacological blockade of alpha2-adrenoceptors induces reinstatement of cocaine-seeking behavior in squirrel monkeys. Neuropsychopharmacology 29:686-693.
21. Leri F, Flores J, Rodaros D, and Stewart J (2002) Blockade of stress-induced but not cocaine-induced reinstatement by infusion of noradrenergic antagonists into the bed nucleus of the stria terminalis or the central nucleus of the amygdala. J Neurosci 22:5713-5718.
22. Liprando LA, Miner LH, Blakely RD, Lewis DA, and Sesack SR (2004) Ultrastructural interactions between terminals expressing the norepinephrine transporter and dopamine neurons in the rat and monkey ventral tegmental area. Synapse 52:233-244.
23. Nally RE, McNamara FN, Clifford JJ, Kinsella A, Tighe O, Croke DT, Fienberg AA, Greengard P, and Waddington JL (2003) Topographical assessment of ethological and dopamine receptor agonist-induced behavioral phenotype in mutants with congenic DARPP-32 "knockout." Neuropsychopharmacology 28:2055-2063.
24. Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, Giros B, Miller GW, and Caron MG (1998) Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci 1:132-137
25. [Comments in Nat Neurosci 1998 Jun;1:90-92; erratum in Nat Neurosci 1998 Aug;1:330].
26. Saitoh A, Onodera K, Morita K, Sodeyama M, and Kamei J (2002) Prazosin inhibits spontaneous locomotor activity in diabetic mice. Pharmacol Biochem Behav 72:365-369.
27. Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R, Lesch KP, Murphy DL, and Uhl GR (1998) Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci U S A 95:7699-7704.
28. Tang C, Mittler T, Duke DC, Zhu Y, Pawlak AP, and West MO (2008) Dose- and rate-dependent effects of cocaine on striatal firing related to licking. J Pharmacol Exp Ther 324:701-713.
29. Teter CJ, McCabe SE, LaGrange K, Cranford JA, and Boyd CJ (2006) Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 26:1501-1510.
30. Tilley MR, Cagniard B, Zhuang X, Han DD, Tiao N, and Gu HH (2007) Cocaine reward and locomotion stimulation in mice with reduced dopamine transporter expression. BMC Neurosci 8:42.
31. Tilley MR and Gu HH (2008) Dopamine transporter inhibition is required for cocaine-induced stereotypy. Neuroreport 19:1137-1140.
32. Torres GE (2006) The dopamine transporter proteome. J Neurochem 97 (Suppl 1):3-10.
33. van der Kooij MA and Glennon JC (2007) Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder. Neurosci Biobehav Rev 31:597-618.
34. Ventura R, Cabib S, Alcaro A, Orsini C, and Puglisi-Allegra S (2003) Norepinephrine in the prefrontal cortex is critical for amphetamine-induced reward and mesoaccumbens dopamine release. J Neurosci 23:1879-1885.
35. Ventura R, Morrone C, and Puglisi-Allegra S (2007) Prefrontal/accumbal catecholamine system determines motivational salience attribution to both reward- and aversion-related stimuli. Proc Natl Acad Sci U S A 104:5181-5186.
36. Volkow ND, Fowler JS, Wang G, Ding Y, and Gatley SJ (2002a) Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord 6 (Suppl 1):S31-S43.
37. Volkow ND, Fowler JS, Wang GJ, Ding YS, and Gatley SJ (2002b) Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol 12:557-566.
38. Wise RA and Bozarth MA (1987) A psychomotor stimulant theory of addiction. Psychol Rev 94:469-492.
39. Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, Miller GW, Wang YM, and Caron MG (2000) Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci 3:465-471.
40. Zhang XY and Kosten TA (2005) Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking. Biol Psychiatry 57:1202-1204.